Loading organizations...
§ Private Profile · 800 Transfer Rd #12, St Paul, MN 55114, USA
Paradigm Diagnostics is a technology company.
Paradigm Diagnostics Inc. provides advanced molecular diagnostic solutions, primarily through its Paradigm Cancer Diagnostic Test (PCDx). This proprietary test performs comprehensive genetic profiling of cancer tumors, utilizing next-generation sequencing to identify actionable mutations. The technical approach allows for rapid results within days and can process specimens with limited tumor material, significantly aiding in the precise characterization of a patient’s cancer.
The company was founded in 2012, with David Mallery serving as President and CEO. The foundational insight stemmed from the critical need for personalized medicine in oncology, recognizing that detailed genetic information from a patient's tumor could dramatically improve treatment efficacy. Paradigm Diagnostics sought to bridge this gap by developing a diagnostic tool that delivers timely, in-depth molecular insights to guide clinical decision-making.
Paradigm Diagnostics serves oncologists and academic medical centers, enabling them to tailor therapies based on the unique genetic landscape of each patient’s cancer. The company's vision is centered on advancing personalized cancer care by equipping clinicians with precise, actionable genomic intelligence, thereby improving outcomes and accelerating the adoption of targeted treatments in oncology.
Paradigm Diagnostics has raised $22.0M across 2 funding rounds.
Paradigm Diagnostics has raised $22.0M in total across 2 funding rounds.
Paradigm Diagnostics has raised $22.0M in total across 2 funding rounds.
Paradigm Diagnostics's investors include BlueStone Venture Partners, John Friedman, Mesa Verde Venture Partners, Stan Lynall, Prairie Ventures, Tech Coast Angels, Carey J. Ng.
Paradigm Diagnostics is a molecular diagnostics company that developed the Paradigm Cancer Diagnostic (PCDx) test, a next-generation sequencing-based genomic profiling tool for patients with advanced, refractory, or recurrent cancer.[1][2][4] It serves oncologists and cancer patients by providing comprehensive molecular profiling, including genome genetic testing and oncology genetic testing, to guide targeted therapies and clinical trial recommendations with smaller sample requirements and faster results than competitors.[1][4] The company, headquartered in Phoenix, Arizona, was founded around 2012-2016, raised $14.4M in funding, and was acquired by Exact Sciences in March 2020, enhancing Exact Sciences' advanced cancer diagnostics portfolio.[1][2][3][4]
Paradigm Diagnostics emerged as a molecular information corporation focused on bringing comprehensive cancer genomic profiling to physicians and patients, addressing gaps in personalized cancer treatment.[2] Founded in 2012 (with some sources noting 2016), it was based in Phoenix at 445 N. 5th Street and quickly advanced its PCDx test, which gained Medicare coverage under Palmetto GBA's MolDx program for next-generation sequencing in solid tumors.[2][4] A pivotal moment came in March 2020 when Exact Sciences acquired it alongside Viomics, integrating Paradigm's scalable clinical lab and therapy selection test into a larger precision oncology platform.[3][4]
Paradigm Diagnostics rode the wave of precision oncology, a trend accelerating in the 2010s toward genomic profiling to personalize cancer care amid rising demands for targeted therapies and immunotherapy.[2][4] Its timing aligned with expanding Medicare coverage for next-generation sequencing tests, reducing barriers for advanced cancer patients and influencing adoption in clinical practice.[4] Market forces like smaller biopsy needs and faster turnaround addressed pain points in tumor profiling, while its acquisition by Exact Sciences amplified impact by merging with established platforms like Cologuard and Oncotype DX, strengthening the ecosystem for end-to-end cancer diagnostics from screening to late-stage therapy selection.[4]
Post-2020 acquisition, Paradigm's PCDx test and team continue evolving within Exact Sciences, likely expanding through commercial scaling, deeper AI integration in biomarker discovery, and broader payer coverage amid growing precision medicine demand.[3][4] Trends like multi-omics profiling and liquid biopsies will shape its trajectory, potentially enhancing therapy matching for rarer cancers. Its influence may grow by powering Exact Sciences' push into deadlier malignancies, solidifying leadership in actionable cancer insights and tying back to its core mission of smarter, faster patient answers.[4]
Paradigm Diagnostics has raised $22.0M across 2 funding rounds. Most recently, it raised $15.0M Series B in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2019 | $15M Series B | — | BlueStone Venture Partners, John Friedman, Mesa Verde Venture Partners, Stan Lynall, Prairie Ventures, Tech Coast Angels | Announced |
| Nov 16, 2016 | $7M Series B | Carey J. NG | — | Announced |